Real world use of targeted therapies in war veterans with kidney cancer
A retrospective study of the use of targeted therapies for [...]
Real world use of pazopanib after immunotherapy for advanced kidney cancer
A study published in Clinical Genitourinary Cancer last month describes [...]
Deciding on the ideal first-line treatment for rare and advanced kidney cancer
Currently, doctors are unsure which is the best first-line treatment [...]
SBRT in combination with systemic treatment for metastatic kidney cancer
Two recent studies have looked at the effect of stereotactic [...]
Panobinostat plus everolimus not effective in metastatic kidney cancer
A recent phase I clinical trial assessed the combination of [...]
PD-L1 can be used to predict the likely course of kidney cancer
A recently published study evaluated the role of programmed-death receptor [...]
MicroRNA as a marker for kidney cancer
A recent study has provided evidence that a group of [...]
SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
